Despite the existence of tumor-specific immune cells, most tumors have devised strategies to avoid immune attack. We demonstrate here that galectin-1 (Gal-1), a negative regulator of T cell activation and survival, plays a pivotal role in promoting escape from T cell-dependent immunity, thus conferring immune privilege to tumor cells. Blockade of immunosuppressive Gal-1 in vivo promotes tumor rejection and stimulates the generation of a tumor-specific T cell-mediated response in syngeneic mice, which are then able to resist subsequent challenge with wild-type Gal-1-sufficient tumors. Our data indicate that Gal-1 signaling in activated T cells constitutes an important mechanism of tumor-immune escape and that blockade of this inhibitory signal can allow for and potentiate effective immune responses against tumor cells, with profound implications for cancer immunotherapy.
Introduction
positive T lymphocytes (Hahne et al., 1996; O'Connell et al., 2001; Andreola et al., 2002; Whiteside, 2002) . However, despite A long-standing paradox in tumor immunology is the growth the wealth of data accumulated in support of the FasL counteratof antigenic tumors in spite of demonstrable antitumor T cell tack hypothesis, many contradictory studies have been reported responses Smyth et al., 2001) . Recent progress showing that FasL can also have proinflammatory and antitutoward an improved understanding of the interactions between moral effects in some contexts (Restifo, 2001 ; Simon et al., tumor cells and the host's immune system has led to the realiza-2002) . To reconcile these conflicting findings, it has been hytion that tumor cells have devised multiple strategies to evade pothesized that the maintenance of immune privilege in tumors immune attack (Marincola et al., 2000; Trapani, 2002; Uytten- relies not only on FasL itself but also on the collective production hove et al., Igney and Krammer, 2002) . Evasion mechaof as yet unidentified immunosuppressive factors (Green and nisms can either be preexisting, arise through outgrowth of Ferguson, 2001; O'Connell et al., 2001) . These inhibitory signals escape mutants, or take place during tumor-sculpting actions by may create an appropriate setting that will prevent the prointhe immune system, in accordance with the recently proposed flammatory effects of FasL, thus favoring immune escape by "cancer immunoediting" hypothesis (Dunn et al., 2002) .
eliminating antitumor effector cells. Accordingly, it has been suggested that the final outcome of an effective antitumor reOne of the most studied strategies of tumor-immune escape is represented by the acquisition of FasL expression that may sponse is determined by a delicate interplay among activating and inhibitory regulatory pathways and that removal of inhibitory enable cancer cells to deliver death signals to activated Fas-signals may be a particularly useful adjunct to other therapeutic pressed Gal-1 ( Figure 1A ), although particularly high expression was detected in murine B16 and human Mel-J and Mel-LES approaches for cancer Phan et al., 2003;  Cheng cell lines. Immunofluorescence staining followed by confocal et al., 2003) . microscopy or flow cytometry revealed a predominant cytoGalectins, a growing family of carbohydrate binding proplasmic and nuclear localization of this protein, although specific teins, have recently attracted the attention of immunologists as labeling was also observed at the cell surface of human and novel regulators of immune cell homeostasis (Liu, 2000) . Despite murine melanoma cells (Figures 1B and 1C) . In addition, we extensive sequence homology and similar carbohydrate specidetected the presence of Gal-1 in concentrated serum-free conficity, various members of this protein family behave as amplifiditioned media (SFCM) from different tumor cell lines ( Figure  ers of the inflammatory response, while others activate homeo-1D). To confirm its identity, we purified this protein from SFCM static signals that serve to shut off immune effector functions of two different cell lines (Mel-J and Mel-LES) by size exclusion (Rabinovich et al., 2002a) . Recently, it has become clear that and affinity chromatography. Amino acid sequence analysis of galectin-1 (Gal-1), a prototype member of this protein family, selected trypsin-digested peptides revealed the complete idenhas the potential to inhibit T cell effector functions by promoting tity of the isolated protein with human placental Gal-1 (see growth arrest and apoptosis of activated T cells (Blaser et al., Supplemental Figure S1 at http://www.cancercell.org/cgi/ 1998; Perillo et al., 1995; Rabinovich et al., 1998 Rabinovich et al., , 2002b , induccontent/full/5/3/241/DC1). Because tumor cell lines grown in ing partial T cell activation (Chung et al., 2000) and/or blocking vitro may not reflect the real state of tumor cells in vivo, we proinflammatory cytokine secretion (Rabinovich et al., 1999a , also tested expression of Gal-1 in human tumor samples. West1999b) . In vivo, therapeutic administration of Gal-1 suppresses ern blot analysis and immunohistochemistry demonstrated high T helper (T H )-1-dependent chronic inflammation in experimental expression of this protein in freshly isolated tumors from melamodels of autoimmunity by increasing T cell susceptibility to noma patients ( Figures 1E and 1F ). activation-induced cell death and skewing the balance of the To investigate the possibility that expression of Gal-1 may immune response toward a T H 2 profile (Rabinovich et al., 1999a;  confer immune privilege to tumor cells, we transfected B16 melanoma cells with Gal-1 antisense cDNA and established 12 Santucci et al., 2003) . different knockdown clones with low or intermediate Gal-1 levels Expression of Gal-1 has been well documented in immune from the heterogeneous population of stably transfected melaprivileged organs (Rabinovich, 1999) and in many different tumor noma cells. Based on Gal-1 expression, we then selected repretypes including astrocytoma (Camby et al., 2001 ) and prostate sentative clones for in vitro and in vivo assays. Western blot (van den Brule et al., 2001) , thyroid (Xu et al., 1995) , colon analysis of supernatants collected from knockdown transfec- (Sanjuan et al., 1997 ), bladder (Cindolo et al., 1999 , and ovary tants revealed decreased levels of Gal-1 secretion ( Figure 2A ). (van den Brule et al., 2003) carcinomas. Interestingly, such exClone one (B16/C1) showed the lowest Gal-1 levels, representpression correlates with the aggressiveness of these tumors ing a relative decrease of ‫%39ف‬ compared to cells transfected and the acquisition of metastatic phenotype.
with empty vector (B16/Ϫ), while clones two and three (B16/ On the basis of these data, we hypothesized that tumor C2 and B16/C3) showed intermediate Gal-1 levels, representing cells may impair T cell effector functions by secretion of Gal-1 relative decreases of ‫%56ف‬ and ‫,%95ف‬ respectively. and that this mechanism may contribute in tilting the balance To evaluate the contribution of Gal-1 to the immunosupprestoward an immunosuppressive environment at the tumor site.
sive and proapoptotic activity of these tumor cell supernatants, Our data provide evidence both in vitro and in vivo of the relewe next incubated activated splenocytes from C57BL/6 (B6) vance of Gal-1-mediated immunosuppression as a novel mechnormal mice for 18 hr with SFCM obtained from control or Gal-1 anism of tumor-immune escape, indicating that blockade of this knockdown transfectants and analyzed the apoptotic T cell poppathway has strong therapeutic potential to shift the balance ulation by double staining using FITC-annexin V and PE-conjuin favor of an efficient T cell-mediated antitumor immune regated anti-CD3 monoclonal antibody (mAb). Supernatants collected from control B16/Ϫ cells induced high levels of T cell sponse. To the best of our knowledge, this is the first in vivo apoptosis (71.0% Ϯ 3.2%), whereas SFCM collected from study demonstrating a link between Gal-1-mediated immunoknockdown transfectants expressing the lowest Gal-1 levels regulation and immune privilege in a setting relevant to cancer (B16/C1) induced only 27.3% Ϯ 2.8% of annexin V staining. immunotherapy.
Remarkably, splenocytes incubated in the presence of SFCM obtained from B16/C2 and B16/C3 underwent apoptotic cell Results death at intermediate levels (40.1% Ϯ 3.9% and 50.8% Ϯ 3.3%, respectively) ( Figure 2B ). These results indicate a functional Identification of Gal-1 as a major immunosuppressive correlation between the levels of Gal-1 in B16 culture supernafactor secreted by human and murine tants and the extent of tumor-induced T cell death.
melanoma cells
To validate this finding in a human setting, we activated Using a specific anti-Gal-1 antibody (Ab), we screened a panel peripheral blood mononuclear cells (PBMCs) with phytohemagof six human and murine melanoma cell lines for Gal-1 expresglutinin (PHA) and then cultured for 18 hr in the presence of sion. We selected melanoma as a tumor model on the basis of different concentrations of SFCM from Mel-LES or Mel-J melaprevious findings reporting the isolation of a low molecular noma cell lines ( Figure 2C ). Activated T cells exposed to Melweight ‫41ف(‬ kDa) immunosuppressive factor from human mela-LES SFCM showed an average of 75.2% Ϯ 4.1% annexin V noma cell supernatants (Morvillo et al., 1996) , whose biochemistaining. Remarkably, when SFCM was preincubated with a cal and functional properties closely resembled those of Gal-1.
neutralizing anti-Gal-1 IgG (Fab) 2 , the percentage of apoptotic T cells decreased to 34.2% Ϯ 5.6%, whereas addition of a Western blot analysis showed that all melanoma cell lines ex- 
A:
Western blot detection of Gal-1 ‫5.41ف(‬ kDa) in total cell lysates (15 g) from human and murine melanoma cell lines using an affinity-purified anti-Gal-1 Ab. Blots incubated with preimmune IgG were used as negative controls. B: Indirect immunofluorescence staining and confocal microscopy after permeabilization of a representative human melanoma cell line (MEL-J) (Scale bar, 70 m). C: Flow cytometry of nonpermeabilized Mel-J and B16 cell lines using an anti-Gal-1 Ab (dark histogram) or control rabbit IgG (empty histogram). D: Western blot detection of concentrated serum-free conditioned medium (SFCM) (15 g) from different melanoma cell lines. E: Western blot analysis of total cell lysates from representative samples obtained from human melanoma patients. F: Immunoperoxidase staining of a paraffinembedded tissue section of a representative human melanoma specimen using an anti-Gal-1 Ab or the same dilution of a control rabbit IgG (magnification, 40ϫ; inset, 100ϫ). Scarce amounts of Gal-1 were detected in normal human melanocytes (data not shown).
control rabbit IgG (Fab) 2 had no effect (data not shown). We 3B). To rule out the possibility that stable transfection with antialso observed a similar reduction in the frequency of annexin sense Gal-1 may directly affect tumor cell growth, we analyzed V positive cells when thiodigalactoside (TDG, a galectin-specific the in vitro cell proliferation of B16/Ϫ and Gal-1 knockdown sugar inhibitor) was incorporated to the culture medium. We clones. All transfectants exhibited a similar growth rate (Figure confirmed these findings by propidium iodide staining of sub-3C), indicating no growth advantage of B16/Ϫ over antisensediploid nuclei (see Supplemental Figure S2 at http://www. transfected tumor cells. In addition, all tumor transfectants grew cancercell.org/cgi/content/full/5/3/241/DC1). In addition, huprogressively at the same rate in immunodeficient nude mice man PBMCs simultaneously exposed to PHA and the indicated (data not shown). stimuli for 72 hr showed a similar outcome in a cell proliferation These results demonstrate that targeted inhibition of Gal-1 assay ( Figure 2D ). expression renders mice resistant to tumor challenge and indiTaken together, these results demonstrate that both murine cate a functional correlation between Gal-1 levels in tumor cells and human melanoma cells secrete functional Gal-1, which suband the extent of in vivo tumor rejection. stantially contributes to the immunosuppressive and proapoptotic activities of these tumor cells.
Tumor rejection induced by Gal-1 blockade requires intact CD4 ؉ and CD8 ؉ T cell responses Targeted inhibition of Gal-1 gene expression renders
In order to investigate the involvement of the immune system mice resistant to tumor challenge in the tumor rejection effect induced by Gal-1 blockade, we To investigate whether tumor cells may overwhelm the antitumor depleted CD4 ϩ , CD8 ϩ , or NK1.1 ϩ cells in vivo and challenged T cell responses in vivo through Gal-1-dependent mechanisms, mice with knockdown transfectants. Depletion of either CD4 ϩ we explored the impact of Gal-1 blockade on tumor progression or CD8 ϩ T cells partially restored B16/C1 cell growth in B6 by injecting B6 mice with representative B16 knockdown mice (Figures 4A and 4B) . Remarkably, depletion of both T cell transfectants. All mice (n ϭ 21) injected subcutaneously with subsets completely abrogated resistance to tumor challenge 2 ϫ 10 5 B16/Ϫ transfectants developed progressively growing induced by Gal-1 blockade and resulted in rapid tumor progrestumors at a rate similar to that of nontransfected B16 cells, sion and similar growth rate as mice injected with B16/Ϫ leading to uniform terminal morbidity by about 20-25 days posttransfectants ( Figures 4A and 4B ). On the other hand, depletion inoculation ( Figures 3A and 3B ). Remarkably, B16/C1 tumor of NK1.1 ϩ cells had only a marginal effect in 3 out of 15 mice transfectants, expressing the lowest Gal-1 levels, were rejected tested ( Figure 4A ). Furthermore, pretreatment of mice with conrapidly and almost completely, since only 2 of 27 mice showed trol mouse IgG did not alter the tumor rejection effect induced tumor growth by day 40. C: Human PBMCs were activated with PHA for 72 hr and then cultured for 18 hr with SFCM from Mel-J in the absence or presence of a neutralizing antiGal-1 (Fab) 2 (10 g/ml) or 30 mM thiodigalactoside (TDG). Positive controls of apoptosis were analyzed in parallel by incubating activated T cells with increasing doses of rGal-1. T cell apoptosis was assessed by double staining using FITC-annexin V and PE-anti-CD3 mAb (*p Ͻ 0.001 Student's t test versus SFCM). D: Human PBMCs were cultured for 72 hr with PHA in the presence of the indicated stimuli and cell proliferation was assessed by ( 3 H)-thymidine uptake. Data are expressed as mean (cpm Ϯ SD) of triplicate determinations (*p Ͻ 0.001 Student's t test versus SFCM).
Blockade of Gal-1 synthesis in tumor cells allows
transfectants produced low levels of IL-2 ( Figure 5B ) and IFN-␥ ( Figure 5C ), lymph node cells from mice inoculated with B16 the generation of a tumor-specific T1-type immune response in vivo knockdown transfectants had greatly enhanced B16-specific T1-type cytokine production. In contrast, no significant differThe immune regulatory effects of Gal-1 and its ability to skew the balance of the immune response toward a T2-type profile ences were found in IL-4 ( Figure 5D ) or IL-5 ( Figure 5E ) levels between both experimental groups. These effects were clearly (Rabinovich et al., 1999a) prompted us to investigate whether resistance to tumor challenge induced by selective Gal-1 blockobserved in tumor-draining lymph nodes, but no significant changes could be detected in lymph nodes distal to tumor sites ade could be associated with an enhancement of a T1-type antitumor response in vivo. For this purpose, we obtained tu-( Figure 5A and data not shown). Furthermore, we could not observe changes in T cell proliferation or cytokine secretion mor-draining and distal lymph nodes from mice inoculated with B16 knockdown or control transfectants. Lymph node cells were when lymph node cells obtained from mice that rejected B16/ C1 transfectants were restimulated ex vivo with syngeneic EL-4 restimulated ex vivo with mitomycin C-treated B16 parental cells and then analyzed for T cell proliferation, cytokine production, thymoma cells ( Figures 5A-5E ). Thus, selective blockade of Gal-1 in tumor cells can stimulate the generation of an otherwise and susceptibility to apoptosis.
Consistent with a role for Gal-1 in tumor-induced immunorepressed tumor-specific T1-type response in tumor-draining lymph nodes. suppression, B16/C1 knockdown cells were more effective than B16/Ϫ tumor cells in stimulating an effective T cell-mediated Since Gal-1 contributes substantially to the proapoptotic activity of melanoma cells (Figure 2 ), we next investigated response, as demonstrated by the greatly increased tumorspecific T cell proliferation ( Figure 5A ). In addition, while tumorwhether tumor-secreted Gal-1 may sensitize T cells in vivo toward an apoptotic phenotype. Tumor-draining lymph nodes draining lymph nodes from mice inoculated with B16/Ϫ from mice treated with Gal-1 knockdown transfectants and furfollowing treatment with B16/Ϫ cells ( Figure 5H ). Thus, tumor ther restimulated with parental B16 cells demonstrated a rerejection induced by Gal-1 blockade is associated with tumor duced T cell susceptibility to apoptosis compared to lymph cell destruction along with an extensive nonapoptotic mononunode cells from mice inoculated with B16/Ϫ Gal-1 sufficient clear cell infiltrate, suggesting an increased availability of surtumor cells ( Figure 5F ). In order to investigate whether the prolifvival signals influencing the antitumor activity at tumor sites. erating antitumor cells were capable of infiltrating tumor sites
To address whether the generation of a tumor-specific T cell and promote tumor cell destruction, and to further explore the response in the absence of Gal-1 is sufficient to stimulate proimpact of Gal-1 blockade on local immune cell apoptosis, we tective immunity to a subsequent challenge with wild-type B16 performed histopathological analysis and TUNEL staining on tumor cells, we rechallenged mice that had previously rejected paraffin-embedded tumor sections from B16/Ϫ and B16/C1-B16/C1 transfectants with the corresponding wild-type tumors treated mice. Ten days after tumor challenge, most peritumoral 20 days after the first exposure. While B16 tumors grew progresmononuclear cells showed apoptotic morphology (4-7 TUNELsively in naive B6 mice, we observed a significant delay in tumor reactive cells/field, 40ϫ) in mice inoculated with B16/Ϫ cells, growth in mice that had been previously exposed to Gal-1 compared to mice injected with B16/C1 (0-1 TUNEL-reactive knockdown transfectants ( Figures 6A and 6B ). cells/field) ( Figures 5G and 5H ). In addition, blockade of Gal-1 Taken together, these results demonstrate that selective was effective at promoting tumor cell destruction accompanied inhibition of Gal-1 gene expression in melanoma cells can allow by extensive melanin release at sites of B16/C1 injection, whereas the integrity of the tumors was completely preserved for and potentiate a tumor-specific T1-type response in synge- T cells are the cytotoxic effectors in melanoma, CD4 ϩ T cells have been shown to mediate CD8 ϩ -independent antitumor efDiscussion fector functions (Hung et al., 1998) . Interestingly, NK cells were not required to promote tumor rejection in our model. However, Here we demonstrate that tumors can overwhelm T cell effector functions through Gal-1-dependent mechanisms. By a combi-IFN-␥ production by NK cells was a critical factor in the development of antitumor immunity following different stimuli, including nation of in vitro and in vivo experiments using knockdown transfectants, we established a link between Gal-1-mediated overexpression of CD70 (Kelly et al., 2002) or NKG2D ligands (Diefenbach et al., 2001 ). Thus, the combination of different immunoregulation and its contribution to tumor-immune privilege. Blockade of the inhibitory effects of Gal-1 within tumor strategies, stimulating both innate and adaptive immune responses (Duguay et al., 2002) but also targeting negative regulatissue resulted in reduced tumor mass and enhanced tumor rejection, stimulating the generation of a potent tumor-specific tory pathways (Pardoll, 2003) , will be necessary to provide complete antitumor protection and allow selective amplification of T1-type response in syngeneic mice.
During the past few years, there has been increasing apimmune responses for successful cancer immunotherapy. An alternative mechanism of enhanced antitumor immunity preciation for the impact of differential T cell glycosylation in the modulation of immune responses (Daniels et al., 2002; Feizi, following removal of the inhibitory effects of Gal-1 could be the emergence of a previously repressed T1-type specific immune 2000). Through interaction with poly-N-acetyllactosamine ligands, created by specific glycosyltransferases (Nguyen et al., response, as we found greatly increased IFN-␥ production by lymph node cells from mice inoculated with Gal-1 knockdown 2001; Lowe, 2001), Gal-1 influences T cell homeostasis by inducing T cell apoptosis (Rabinovich et al., 1999a) , blocking transfectants. This finding strengthens the hypothesis that an IFN-␥-mediated response is critical to prevent tumor formation T cell activation (Chung et al., 2000) , inhibiting proinflammatory cytokine secretion (Rabinovich et al., 1999b) , and favoring turnand shape tumor immunogenicity (Shankaran et al., 2001; Hu et al., 1998) and may counteract the gradual loss of T H 1 populaover of activated leukocytes (Dias-Baruffi et al., 2003) . Therefore, the stimulation of an effective antitumor response following tions observed during tumor progression (Ghosh et al., 1995) . Interestingly, we have previously shown that recombinant Gal-1 downregulation of Gal-1 could be attributed to several nonexclusive mechanisms. While this effect may be a consequence of and its genetic delivery suppress T H 1-mediated inflammation in experimental models of collagen-induced arthritis and TNBSthe removal of an inhibitory signal involved in T cell death, it is equally likely to result from the activation of a larger number of induced colitis (Rabinovich et al., 1999a; Santucci et al., 2003) . In these models, Gal-1 administration resulted in a selective naive T cells due to a lowering of the threshold for activation. In this context, Gal-1 blockade may increase both the survival elimination of antigen-activated T cells and in a T H 2 shift that induced a remission state in the evolution of the ongoing inand frequency of helper and cytotoxic T cells, which could act in concert to orchestrate the host response against tumors. flammatory disease. Since Gal-1 was effective at promoting apoptosis of effector Accordingly, depletion experiments revealed the requirement for both CD4 ϩ and CD8 ϩ T cells to promote tumor rejection T cells in autoimmune settings, it may be possible that blockade of this inhibitory pathway may allow the recruitment and activain our model, suggesting that both T cell subsets could be 
tion of low-affinity autoreactive T cells that might have escaped
The data presented here demonstrate that melanoma cells may take advantage of Gal-1 expression for inducing apoptosis tolerance induction. Although we have not found signs of tissuespecific self reactivity in our model, a long-term follow up will of tumor-specific effector T cells and that this mechanism may contribute in tilting the balance toward an immunosuppressive be necessary to investigate whether mice that rejected challenge with melanoma transfectants will develop signs of autoimenvironment at the tumor site. However, we cannot rule out the possibility that alternative Gal-1-dependent mechanisms may mune depigmentation, as described for other immunotherapy strategies (Ramirez-Montagut et al., 2003) .
contribute to tumor progression. In accordance, previous stud- (Camby et al., 2001) , and tumor cell proliferation (Kopitz et cytomegalovirus (CMV) promoter of a HindIII/BamH1-cut pcDNA3 expresal., 2001) in vitro. Furthermore, since human tumors express a sion vector (Invitrogen) as described (Rabinovich et al., 1999a) . A clone in complex pattern of galectin expression , futhe antisense orientation was obtained from pcDNA3-Gal-1, excised with ture studies are warranted to elucidate the immunoregulatory BamH1 and EcoRV, and subcloned into the CMV-driven pcDNA6 expression vector (Invitrogen) to create the plasmid p6/G1-As.
properties of other members of the galectin family (Fukumori et Subconfluent B16 cells were transfected with p6/G1-As using Lipofecal., 2003) and their contribution to tumor-immune privilege. novel tumor-associated molecules to tumor-immune evasion, including B7-H1 (Dong et al., 2002) and the enzyme indoleamine a peroxidase-labeled anti-rabbit IgG (BioRad) and developed using an enhanced chemoluminescence detection kit (Amersham). Films were analyzed Experimental procedures with the Scion Image Analysis software, and the intensity of each band was recorded and expressed as arbitrary units (AU). Recombinant Gal-1 (rGal-1) Tumor cell lines was used as a positive control of immunodetection. Equal loading was The human melanoma cell lines IIB-Mel-LES, IIB-Mel-J, and IIB-Mel-IAN checked by Ponceau S staining or by incubation of the blots with an anti-␣ were established from human metastatic melanomas as described (Guerra tubulin mAb (Sigma). et al., 1989; Kariyama et al., 1995; Ledda et al., 1997) , SKMel28 was obtained from ATCC, and the A375N cell line was a gift from Dr. E. Medrano. The
Immunofluorescence staining and confocal microscopy murine B16 melanoma cell line was obtained from ATCC and the EL-4
Tumor cells were washed twice in PBS and fixed in 2% paraformaldehyde for 15 min on ice. Cells were then stained with a 1:500 dilution of a rabbit thymoma was a gift from Dr. C. Milstein. Both murine cell lines are syngeneic anti-Gal-1 Ab (or control rabbit IgG) for 30 min on ice and then incubated to C57BL/6 (B6) background.
with a FITC-conjugated goat anti-rabbit IgG (Cappel). In each experiment, 10 4 viable cells were processed for FACS analysis in a FACSCalibur flow Mice Eight-to ten-week-old inbred female C57BL/6 (H-2b) mice were used in cytometer (Becton Dickinson). For confocal microscopy, tumor cells were cultured overnight on glass coverslips washed with PBS, fixed with 4% this study. Animals were maintained at the Animal Resource Facilities (Institute Leloir) in accordance with the experimental ethics committee guidelines.
paraformaldehyde for 10 min, permeabilized using PBS containing 0.2% Triton X-100, and stained as described above, except that donkey antiIn vivo lymphocyte subset depletion rabbit Cy2 (Jackson) was used as secondary Ab. Color confocal and trans-CD4 ϩ , CD8 ϩ , or NK1.1 ϩ cells were depleted in vivo by intraperitoneal adminmitted light images were acquired with the use of a Zeiss LSM 510 microistration of 0.2 mg of mAbs against CD4 (clone YTS 191.1; ATCC), CD8 scope (Jena, Germany) with C-apochromat 63ϫ/1.2 W objective. The image (clone YTS 169.4; ATCC), or NK1.1 (clone 4D11; ATCC) at days Ϫ1, 1, 8, size was set to 1024 pixels with 8 bits pixel depth.
15, and 22, relative to tumor inoculation as described (Diefenbach et al., 2001) . Control mice received equivalent amounts of normal mouse IgG at Protein purification and amino acid sequence analysis the same days. Depletions were confirmed in lymph nodes and spleen cells Serum-free culture medium was collected from semiconfluent monolayers 7 days after tumor challenge by flow cytometry using non crossreactive Abs. of Mel-J or Mel-LES cell lines, processed as described (Morvillo et al., 1996) , In general, less than 1.7% of the depleted cell population could be detected and subjected to size-exclusion chromatography (Superose 12HR 10/30 in spleen and lymph nodes, whereas mice treated with control IgG demoncolumn, Pharmacia). The eluted low molecular weight fraction was concenstrated unchanged lymphocyte profiles. Kaplan-Meier analysis was pertrated and applied to a lactosyl-Sepharose column (Sigma) to enrich for formed as described above. Results are expressed as mean Ϯ SD from two ␤-galactoside binding proteins. After elution with lactose, one major peak independent experiments with n ϭ 5 mice in each group per experiment. was obtained, which was subjected to trypsin digestion and amino acid sequence analysis, as described (Rabinovich et al., 1998) 
. Tryptic peptides
In situ TUNEL labeling, histopathology, were separated by reverse phase HPLC on a Brownlee C18 column, applied and immunohistochemistry to a Polybrene-coated glass filter, and sequenced in an Applied Biosystems Ten days after tumor challenge, palpable tumors of mice inoculated with model 477A automatic sequencer.
B16/Ϫ or sites of tumor injection of mice inoculated with B16/C1 were removed, paraffin-embedded, and processed for histological examination Lymphocyte preparation and activation and apoptosis detection by a peroxidase-conjugated in situ TUNEL assay Splenocytes from B6 mice were prepared by mechanical disruption of (Intergen) according to the manufacturer's instructions. Representative tisspleens using standard protocols. For apoptosis assays, splenocytes (5 ϫ sue samples for each treatment were also stained with hematoxylin and 10 6 cells/ml) were activated with Con A (5 g/ml) for 72 hr and then cultured eosin. Qualitative and quantitative studies of stained sections were perfor 18 hr in the absence or presence of optimal dilutions (1:2) of SFCM formed in a blinded fashion by a medical pathologist on five or more samples derived from an equal cell number of knockdown or control transfectants.
from distinct mice, and the number of TUNEL-reactive mononuclear cells Human PBMCs were isolated from healthy donors by Ficoll-Paque Plus per field (40ϫ) was recorded. Immunoperoxidase staining was performed (Amersham) gradient centrifugation, washed, and resuspended in complete on paraffin-embedded tissue sections from human melanoma samples using RPMI 1640 medium. Cells (1 ϫ 10 6 cells/ml) were then stimulated for 72 hr the anti-Gal-1 Ab (1:500) or the same dilution of a control rabbit IgG. The with 1 g/ml PHA (Sigma) and further cultured for 18 hr in the presence of avidin-biotin peroxidase complex was used according to the manufacturer's optimal dilutions of SFCM (1:2) collected from human Mel-J and Mel-LES recommended instructions (ABC Vectastatin, Vector). cell lines. In neutralization experiments, melanoma cell supernatants were added to PBMCs in the presence of 30 mM TDG (Sigma) or saturating MTT assay amounts (10 g/ml) of a blocking anti-Gal-1 IgG (FabЈ) 2 prepared using the Tumor cell growth in vitro was measured by the colorimetric MTT assay. Immobilized Pepsin kit (Pierce) or (FabЈ) 2 fragment of a control rabbit IgG.
Briefly, exponentially growing control or knockdown transfectants were thorAfter incubation with different stimuli, cells were washed with sterile PBS oughly washed and incubated for 24 hr in serum-free medium to synchronize containing 30 mM lactose to dissociate cell clusters and processed for cell growth. Thereafter, 10 3 cells/well were cultured in 96-well plates in apoptosis detection. As control of Gal-1-induced apoptosis, activated complete DMEM. Cell growth was determined at 24 hr intervals by replacing PBMCs were exposed to different doses of rGal-1 as described (Rabinovich the culture medium with 0.1 ml of MTT solution (Sigma). Cell lines were then et al., 2002b) . To analyze cell proliferation, PBMCs were cultured for 72 hr incubated at 37ЊC for 2 hr and exposed to 200 l of solubilizer solution (90% either with PHA (1 g/ml) or an anti-CD3 mAb (25 ng/ml; Becton Dickinson) isopropanol, 20% DMSO, 4% Tween 20), and absorbance was determined at in the presence of the indicated stimuli. Then cultures were pulsed with 1 562 nm. Ci/ml (methyl-3 H) thymidine (specific activity 50 Ci/mmol; New England Nuclear) for the last 16 hr. Results are expressed as cpm Ϯ SD of triplicate Ex vivo analysis of T cell proliferation and apoptosis determinations.
Tumor-draining or distal lymph nodes were obtained from mice injected with knockdown or control transfectants 2 weeks after tumor challenge. Lymph Apoptosis assays node cells were prepared using standard protocols and analyzed for T cell T cell apoptosis was evaluated by a double staining procedure using the proliferation, cytokine production, and susceptibility to apoptosis. Briefly, FITC-annexin V binding assay (Immunotech) and PE-conjugated anti-CD3 cells (5 ϫ 10 5 /well) were stimulated in RPMI 1640 complete medium with mAb. The percentage of nuclei with subdiploid DNA content was determined mitomycin C-treated B16 parental cells (5 ϫ 10 5 /well) or mitomycin C-treated by propidium iodide (PI) staining. Briefly, cells were gently resuspended in EL-4 cells (5 ϫ 10 5 /well). After 5 days, cultures were pulsed with 1 Ci/ml 1 ml hypotonic fluorochrome solution (50 g/ml PI diluted in 0.1% sodium (methyl-3 H) thymidine (specific activity 50 Ci/mmol; New England Nuclear) citrate plus 0.1% Triton X-100) and kept at 4ЊC for 3 hr in the dark. Ten for the last 16 hr. Incorporation of radioactivity was measured in a liquid thousand events were acquired in a FACSCalibur flow cytometer.
scintillation ␤-counter (Packard Instruments) and expressed as cpm Ϯ SD of triplicate determinations. Susceptibility to apoptosis was assessed by In vivo tumor challenge annexin V and PI staining, following restimulation of lymph node cells with Melanoma tumors were established in B6 mice by subcutaneous injection mitomycin C-inactivated B16 cells for 72 hr. of 2 ϫ 10 5 cells in 50 l of sterile PBS into the right flank. Mice were challenged with B16/Ϫ transfectants (n ϭ 21; seven mice per experiment)
Cytokine assays or independent knockdown clones (n ϭ 27; nine mice per experiment).
Lymph node cells (5 ϫ 10 5 /well) taken from mice inoculated with knockdown Representative clones used for challenge were selected on the basis of or control transfectants were restimulated with or without mitomycin Gal-1 expression. Tumor development was monitored every second day by C-inactivated B16 (5 ϫ 10 5 /well) or EL-4 cells (5 ϫ 10 5 /well). After 72 hr, cellmeasuring tumor perpendicular diameters with a metric caliper. Tumor volfree supernatants were collected and subjected to cytokine determination ume was estimated as (d 2 ϫ D ϫ 0.5), where d and D are the minor and (IFN-␥, IL-2, IL-4 and IL-5) using specific capture ELISA kits (Pharmingen), major diameters, respectively. For ethical reasons, animals were sacrificed according to the manufacturer's instructions. Data are given as the mean when tumors reached a volume greater than 2 cm 3 . Mice with tumor volume of triplicate measurements of three independent experiments. less than 0.5 cm 3 were considered as tumor free for the Kaplan-Meier analysis. For rechallenge experiments, groups of five mice that had completely Statistical analysis rejected the initial tumor (20 days after first inoculation) were injected in the Comparison of two groups was made using Student's t test for unpaired data opposite flank with wild-type B16 tumor cells. Age-matched naive mice injected with B16 tumor cells were used as controls.
when appropriate. Kaplan-Meier analysis was used to establish statistical 
